First VMS+3.0 in UK and Seventh Hospital to Adopt the Latest VMS Technology
Toronto, Ontario – TheNewswire – January 4, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that the Company’s proprietary VMS+3.0 whole-heart analysis system has been installed at Kings College Hospital (KCH) in London. KCH is a major research and clinical centre in the UK.
“This will help us evaluate patients with COVID-19, who are known to have acute right-heart dilation and systolic dysfunction, and many develop chronic symptoms,” stated Dr. Mark Monaghan, Director of Non-Invasive Cardiology at KCH. “It is important to compare the response of the heart to COVID-19 with other known heart conditions, which can also be assessed with the VMS+3.0.”
The NHS in the UK has announced an initiative to open 40 new specialist clinics for COVID-19 patients with continuing symptoms, “long COVID”, to build an expertise in assessing and treating long-COVID patients (https://www.england.nhs.uk/2020/11/nhs-launches-40-long-covid-clinics-to-tackle-persistent-symptoms/). A study from King’s College London found that older people, women and those with a greater number of different symptoms in the first week of their illness were more likely to develop long COVID with one in 10 still unable to shake off the side effects eight weeks after infection.
The Company estimates that 40,000 VMS+3.0 units would be required based on standard-of-care guidelines to effectively diagnose, monitor and manage the health of patients with congenital heart disease, pulmonary hypertension, suffering cardiotoxicity due to chemotherapy and COVID-19 infected patients.
About Kings College Hospital London
King's College Hospital (KCH) is a major trauma centre in Denmark Hill, Camberwell in the London Borough of Lambeth. It serves an inner city population of 700,000 in the London boroughs of Southwark and Lambeth, and also serves as a tertiary referral centre in certain specialties to millions of people in southern England. It is a large teaching hospital and is, with Guy's Hospital and St. Thomas' Hospital, the location of King's College London School of Medicine and one of the institutions that comprise the King's Health Partners, an academic health science centre.
KCH is a centre of excellence for heart disease and primary angioplasty. It recently became one of the first hospitals in London to use a biodegradable heart stent, which dissolves after the vessel has healed and no longer needs support. In tandem with our cardiac colleagues at Guy's and St Thomas' NHS Foundation Trust, King's also runs the largest aortic valve replacement programme in the UK.
The Harris Birthright Unit at KCH is one of the largest fetal medicine units of its kind in the world, seeing 15,000 women and their unborn babies each year. The unit provides specialist testing and treatment for babies with abnormalities in the womb, including heart defects.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Mr. Jonathan Robinson
Phone: (416) 669-1001
Mr. Clay Chase
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.